ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Nov 13, 2019||ENDRA Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results|
|Nov 05, 2019||ENDRA Life Sciences to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13, 2019 at 4:30 p.m. ET|
|Nov 04, 2019||ENDRA Life Sciences to Host Key Opinion Leader (KOL) Event in Conjunction with the Annual 2019 AASLD Liver Meeting|
|Oct 14, 2019||ENDRA Life Sciences to present at H.C. Wainwright 3rd Annual NASH Investor Conference|
|Sep 26, 2019||ENDRA Life Sciences Reports Completion and Top Level Findings of Second Phase of Robarts Research Institute Liver Fat Feasibility Study|
|Day Range||0.9100 - 0.9500|
|52 Week Range||0.6211 - 3.4857|
|Bid/Ask||0.9300 / 0.9399|
|Bid/Ask Size||2,500 X 100|
|Market Cap||6.99 million|
|Shares Outstanding||7.52 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|